Last A$0.14 AUD
Change Today 0.00 / 0.00%
Volume 307.8K
NRT On Other Exchanges
Symbol
Exchange
NASDAQ CM
OTC US
Frankfurt
Stuttgart
As of 1:59 AM 10/2/14 All times are local (Market data is delayed by at least 15 minutes).

novogen ltd (NRT) Snapshot

Open
A$0.14
Previous Close
A$0.14
Day High
A$0.14
Day Low
A$0.14
52 Week High
11/14/13 - A$0.40
52 Week Low
07/21/14 - A$0.12
Market Cap
23.6M
Average Volume 10 Days
140.4K
EPS TTM
A$-0.05
Shares Outstanding
168.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVOGEN LTD (NRT)

Related News

No related news articles were found.

novogen ltd (NRT) Related Businessweek News

No Related Businessweek News Found

novogen ltd (NRT) Details

Novogen Limited is engaged in the pharmaceutical research and development business in Australia. The company has primarily two drug technology platforms, which include super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). Its SBPs technology platform offers drug candidates, which include Cantrixil, an intra-peritoneal product intended for the treatment of abdominal cancers, such as ovarian and pancreatic cancer; Trilexium that is intended for the treatment of neural cancers, including glioblastoma and neuroblastoma; and Trx-7 for the treatment of prostate cancer. The company’s ATMs technology platform targets the cytoskeleton of the cancer cell. Novogen Limited was founded in 1994 and is based in Hornsby, Australia.

Founded in 1994

novogen ltd (NRT) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: A$332.8K
Company Secretary
Total Annual Compensation: A$57.5K
Vice-President of Drug Discovery, Manufacture...
Total Annual Compensation: A$279.0K
Director of ATM Program
Total Annual Compensation: A$52.5K
Chief Scientific Officer
Total Annual Compensation: A$200.0K
Compensation as of Fiscal Year 2014.

novogen ltd (NRT) Key Developments

Novogen Limited - Special Call

To review strategies for R&D, clinical trials and company growth

Novogen Limited Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 02:45 PM

Novogen Limited Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 02:45 PM. Venue: Congress Center Basel, MCH Messe Schweiz (Basel) AG, CH-4005 Basel, Switzerland. Speakers: Graham Edmund Kelly, Chairman and Chief Executive Officer.

Novogen Limited, Special/Extraordinary Shareholders Meeting, Aug 13, 2014

Novogen Limited, Special/Extraordinary Shareholders Meeting, Aug 13, 2014., at 14:00 AUS Eastern Standard Time. Location: AT THE OFFICES OFCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED. Agenda: To consider subsequent approval of issues of conversion shares; to consider approval of issue of new shares and attaching warrants; and to transact any other business as may be brought before the Meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NRT:AU A$0.14 AUD 0.00

NRT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NRT.
View Industry Companies
 

Industry Analysis

NRT

Industry Average

Valuation NRT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 51.0x
Price/Book 14.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 39.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVOGEN LTD, please visit www.novogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.